NL-OMON25584招募中不适用
The effect of recombinant factor IX-FIAV in in vitro thrombin generation in hemophilia Apatient samples; FIVITAS
Erasmus University Medical Center Rotterdam0 个研究点目标入组 21 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Age 18 years or older hemophilia A patients
- •- Male sex
- •- Mentally capable of informed consent
排除标准
- •- Prophylactic treatment with FVIII, with less than 48 hours washout period between dosages of FVIII
- •- Patients receiving bypassing therapy such as prothrombin complex (FEIBA), eptacog alfa (NovoSeven) or emicizimab (Hemlibra)
- •- Any other known hemostatic disorder, inherited or acquired (such as acquired von Willebrand disease etc…)
- •- Any known liver disease, leading to acute or chronic liver disfunction and/or failure
研究者
相似试验
招募中
不适用
The effect of recombinant Factor IX-FIAV in In-vitro thrombin generation in hemophilia A patient samplesHemophilia ANL-OMON47946Erasmus MC, Universitair Medisch Centrum Rotterdam21
已完成
3 期
A clinical trial to study the effects of IB1001,in previously treated patients children with Hemophilia BCTRI/2011/06/001832Aptevo Bio Therapeutics LLC22
进行中（未招募）
1 期
Study of a new medicinal factor IX product, IB1001, to treat patients with hemophilia BEUCTR2010-024190-39-GBAptevo Europe Limited22
已完成
不适用
Preventive Therapy In Hemophilia B using very low dose Factor IX.CTRI/2020/06/025789Maulana Azad Medical College20
已完成
3 期
The comparison of efficacy between Novoseven® and Recombinant factor VIIa (Aryogen)congenital FVII deficiency.Hereditary deficiency of other clotting factorsIRCT201104266302N1AryoGen Biopharma Company66